JAK inhibr safety review - Meta-analysis shows a significant 57% increase in risk of H. zoster with JAKi (RR 1.57; 1.04-2.37). Data from 82 studies, 66,159 pts w/ RA, IBD, Pso, PsA, AS. Rates of SIE=2.81/100PY and HZ=2.67/100 PY. No increase in mortality https://t.co/Tyb0VDlJOT
Links:
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases …
https://bit.ly/3cXqvAE
May-21-2020


